Chi Soo Kang1, Yunwei Chen1, Hyunbeom Lee1, Dijie Liu2, Xiang Sun1, Junghun Kweon1, Michael R Lewis3, Hyun-Soon Chong4. 1. Chemistry Division, Biological and Chemical Sciences Department, Illinois Institute of Technology, Chicago, IL. 2. Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO. 3. Research Service, Harry S. Truman Memorial Veterans' Hospital; Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO. 4. Chemistry Division, Biological and Chemical Sciences Department, Illinois Institute of Technology, Chicago, IL. Electronic address: Chong@iit.edu.
Abstract
INTRODUCTION: Therapeutic potential of β-emitting cytotoxic radionuclides (90)Y and (177)Lu has been demonstrated in numerous preclinical and clinical trials. A bifunctional chelate that can effectively complex with the radioisotopes is a critical component for molecular targeted radiotherapy (90)Y and (177)Lu. A new bifunctional chelate 5p-C-NETA with a relatively long alkyl spacer between the chelating backbone and the functional unit for conjugation to a tumor targeting moiety was synthesized. 5p-C-NETA was conjugated to a model targeting moiety, a cyclic Arg-Gly-Asp-D-Tyr-Lys (RGDyK) peptide binding integrin αvβ3 protein overexpressed on various cancers. 5p-C-NETA was conjugated to c(RGDyK) peptide and evaluated for potential use in molecular targeted radiotherapy of (90)Y and (177)Lu. METHODS: 5p-C-NETA conjugated with c(RGDyK) was evaluated in vitro for radiolabeling, serum stability, binding affinity, and the result of the in vitro studies of 5p-C-NETA-c(RGDyK) was compared to that of 3p-C-NETA-c(RGDyK). (177)Lu-5p-C-NETA-c(RGDyK) was further evaluated for in vivo biodistribution using gliobastoma bearing mice. RESULT: The new chelate rapidly and tightly bound to a cytotoxic radioisotope for cancer therapy, (90)Y or (177)Lu with excellent radiolabeling efficiency and maximum specific activity under mild condition (>99%, RT, <1 min). (90)Y- and (177)Lu-radiolabeled complexes of the new chelator remained stable in human serum without any loss of the radiolanthanide for 14 days. Introduction of the tumor targeting RGD moiety to the new chelator made little impact on complexation kinetics and stability with (90)Y or (177)Lu. (177)Lu-radiolabeled 5p-C-NETA-c(RGDyK) conjugate was shown to target tumors in mice and produced a favorable in vivo stability profile. CONCLUSION: The results of in vitro and in vivo evaluation suggest that 5p-C-NETA is an effective bifunctional chelate of (90)Y and (177)Lu that can be applied for generation of versatile molecular targeted radiopharmaceuticals.
INTRODUCTION: Therapeutic potential of β-emitting cytotoxic radionuclides (90)Y and (177)Lu has been demonstrated in numerous preclinical and clinical trials. A bifunctional chelate that can effectively complex with the radioisotopes is a critical component for molecular targeted radiotherapy (90)Y and (177)Lu. A new bifunctional chelate 5p-C-NETA with a relatively long alkyl spacer between the chelating backbone and the functional unit for conjugation to a tumor targeting moiety was synthesized. 5p-C-NETA was conjugated to a model targeting moiety, a cyclic Arg-Gly-Asp-D-Tyr-Lys (RGDyK) peptide binding integrin αvβ3 protein overexpressed on various cancers. 5p-C-NETA was conjugated to c(RGDyK) peptide and evaluated for potential use in molecular targeted radiotherapy of (90)Y and (177)Lu. METHODS:5p-C-NETA conjugated with c(RGDyK) was evaluated in vitro for radiolabeling, serum stability, binding affinity, and the result of the in vitro studies of 5p-C-NETA-c(RGDyK) was compared to that of 3p-C-NETA-c(RGDyK). (177)Lu-5p-C-NETA-c(RGDyK) was further evaluated for in vivo biodistribution using gliobastoma bearing mice. RESULT: The new chelate rapidly and tightly bound to a cytotoxic radioisotope for cancer therapy, (90)Y or (177)Lu with excellent radiolabeling efficiency and maximum specific activity under mild condition (>99%, RT, <1 min). (90)Y- and (177)Lu-radiolabeled complexes of the new chelator remained stable in human serum without any loss of the radiolanthanide for 14 days. Introduction of the tumor targeting RGD moiety to the new chelator made little impact on complexation kinetics and stability with (90)Y or (177)Lu. (177)Lu-radiolabeled 5p-C-NETA-c(RGDyK) conjugate was shown to target tumors in mice and produced a favorable in vivo stability profile. CONCLUSION: The results of in vitro and in vivo evaluation suggest that 5p-C-NETA is an effective bifunctional chelate of (90)Y and (177)Lu that can be applied for generation of versatile molecular targeted radiopharmaceuticals.
Authors: B D Palmer; H H Lee; P Johnson; B C Baguley; G Wickham; L P Wakelin; W D McFadyen; W A Denny Journal: J Med Chem Date: 1990-11 Impact factor: 7.446
Authors: Marcel L Janssen; Wim J Oyen; Ingrid Dijkgraaf; Leon F Massuger; Cathelijne Frielink; D Scott Edwards; Milind Rajopadhye; Henk Boonstra; Frans H Corstens; Otto C Boerman Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: Chi Soo Kang; Hyun A Song; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel; Hyun-Soon Chong Journal: Nucl Med Biol Date: 2013-03-27 Impact factor: 2.408
Authors: R D Alvarez; E E Partridge; M B Khazaeli; G Plott; M Austin; L Kilgore; C D Russell; T Liu; W E Grizzle; J Schlom; A F LoBuglio; R F Meredith Journal: Gynecol Oncol Date: 1997-04 Impact factor: 5.482
Authors: Thaddeus J Wadas; Hongju Deng; Jennifer E Sprague; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson Journal: J Nucl Med Date: 2009-11 Impact factor: 10.057
Authors: Lily Li; María de Guadalupe Jaraquemada-Peláez; Eduardo Aluicio-Sarduy; Xiaozhu Wang; Todd E Barnhart; Weibo Cai; Valery Radchenko; Paul Schaffer; Jonathan W Engle; Chris Orvig Journal: Dalton Trans Date: 2020-04-09 Impact factor: 4.390